FDA launches pilot program to accelerate drug approval timelines

The FDA is accepting applications for a pilot program aimed at shortening drug approval times, positioning the U.S. to compete with faster regulators in China and Australia. The program's scope and criteria are not yet detailed, and its impact on approval speed and drug access remains uncertain. This marks a notable shift in FDA regulatory posture toward efficiency, potentially affecting pharmaceutical innovation and market dynamics.